LCA activity
Recent labor-condition rows help reveal roles, worksites, wages, and case statuses. LCA certification is not USCIS petition approval.
Imported LCA rows
31
Median wage
$188,781
Source period
FY2026 Q2
H-1B/LCA filing signal: As of source verification 2026-06-25, Takeda Pharmaceuticals shows 31 imported DOL labor-condition rows through FY2026 Q2 on VisaSignal. The largest role bucket is Assoc. Dir., Sci. & Competitive Analysis, Glbl Oncology (2 rows). The largest worksite bucket is Cambridge, MA (20 rows). Treat this as historical H-1B/LCA filing activity, not proof of USCIS petition approval or future sponsorship.
Wage range
Normalized from 33 imported LCA wage rows. DOL-disclosed offered and prevailing wages span different roles, worksites, and wage units — read the band as wage-distribution context, not a guaranteed offer or legal minimum.
25th percentile
$170,000
Median
$188,781
75th percentile
$208,220
Range
$137,000 – $246,000
H-1B evidence checklist
For searches like "Takeda Pharmaceuticals H-1B", "Takeda Pharmaceuticals LCA", or "does Takeda Pharmaceuticals sponsor H-1B", read the filing count, role/worksite pattern, and status mix together before treating the employer as a lead.
For "Takeda Pharmaceuticals H-1B" or "Takeda Pharmaceuticals LCA" research, 31 imported DOL LCA rows through FY2026 Q2 show labor-condition activity attributed to this normalized employer name. Use the count as a historical filing signal, not a hiring promise.
Read source caveatsAssoc. Dir., Sci. & Competitive Analysis, Glbl Oncology (2 rows) and Cambridge, MA (20 rows) are the strongest role and worksite signals. Compare those row-level patterns with the wage band before treating Takeda Pharmaceuticals as relevant to your target role or location.
Compare salary signalsCertified represents 94% of the displayed LCA rows. DOL LCA certification is not USCIS H-1B petition approval, so read the status mix with row dates and source period before treating Takeda Pharmaceuticals as a sponsor lead. Then compare the employer against the broader H-1B sponsor database before shortlisting.
Browse H-1B sponsorsUse the full LCA and PERM database lookup when you need to search Takeda Pharmaceuticals rows across job titles, SOC codes, worksites, and states instead of relying only on this employer summary.
Open LCA database lookupLCA query context
For searches like "Takeda Pharmaceuticals LCA", start with the official filing count, then compare role, worksite, wage, and status signals before opening individual rows.
Assoc. Dir., Sci. & Competitive Analysis, Glbl Oncology is the largest imported role bucket with 2 matching rows.
Cambridge, MA is the largest imported worksite cluster with 20 matching rows.
See other H-1B sponsors in Massachusetts.
Certified is the largest observed case-status bucket, representing 94% of 31 displayed LCA rows.
Status mix is the share of displayed official DOL LCA rows by case outcome; for Takeda Pharmaceuticals, Certified accounts for 94% of the recent LCA rows shown here as of source verification .
| Case | Status | Decision | Role | Worksite | Wage | Source |
|---|---|---|---|---|---|---|
| I-200-26072-702929 | Certified | Mar 20, 2026 | Technology Lead - Quality Systems | Lexington, MA | $188,977 | FY2026 Q2 |
| I-200-26041-630517 | Certified | Feb 18, 2026 | Head of Enterprise Strategy Enablement, Commercial | Cambridge, MA | $235,068 | FY2026 Q2 |
| I-200-26008-545853 | Certified | Jan 15, 2026 | Quality Control Manager | Lexington, MA | $146,789 | FY2026 Q2 |
| I-200-25352-495420 | Certified | Dec 26, 2025 | Product Manager | Cambridge, MA | $188,781 | FY2026 Q1 |
| I-200-25352-494048 | Certified | Dec 26, 2025 | Executive Medical Science Liaison | Cambridge, MA | $208,220 | FY2026 Q1 |
| I-200-25352-494055 | Certified | Dec 26, 2025 | Director, GPD DDT Medical GI TA | Cambridge, MA | $225,000 | FY2026 Q1 |
| I-200-25352-495420 | Certified | Dec 26, 2025 | Product Manager | Cambridge, MA | $188,781 | FY2026 Q2 |
| I-200-25352-494048 | Certified | Dec 26, 2025 | Executive Medical Science Liaison | Cambridge, MA | $208,220 | FY2026 Q2 |
| I-200-25352-494055 | Certified | Dec 26, 2025 | Director, GPD DDT Medical GI TA | Cambridge, MA | $225,000 | FY2026 Q2 |
| I-200-25346-478033 | Certified | Dec 19, 2025 | Senior Manager, Field Operations & Solutions | Lexington, MA | $175,473 | FY2026 Q2 |
| I-200-25346-478033 | Certified | Dec 19, 2025 | Senior Manager, Field Operations & Solutions | Lexington, MA | $175,473 | FY2026 Q1 |
| I-200-25335-447592 | Certified | Dec 8, 2025 | Network Platform Owner “ LAN and Automation | Leander, TX | $182,000 | FY2026 Q1 |
| I-200-25335-447592 | Certified | Dec 8, 2025 | Network Platform Owner – LAN and Automation | Leander, TX | $182,000 | FY2026 Q2 |
| I-200-25330-440741 | Certified | Dec 4, 2025 | USBU DD&T Data Products and Services Lead | Cambridge, MA | $225,570 | FY2026 Q2 |
| I-200-25330-440741 | Certified | Dec 4, 2025 | USBU DD&T Data Products and Services Lead | Cambridge, MA | $225,570 | FY2026 Q1 |
| I-200-25329-435867 | Certified | Dec 3, 2025 | Senior Manager, IBD Analytics | Cambridge, MA | $162,552 | FY2026 Q1 |
| I-200-25329-435867 | Certified | Dec 3, 2025 | Senior Manager, IBD Analytics | Cambridge, MA | $162,552 | FY2026 Q2 |
| I-200-25324-425297 | Certified | Nov 28, 2025 | Service Governance Lead | Lexington, MA | $207,517 | FY2026 Q2 |
| I-200-25324-425297 | Certified | Nov 28, 2025 | Service Governance Lead | Lexington, MA | $207,517 | FY2026 Q1 |
| I-200-25310-382198 | Certified | Nov 14, 2025 | Platform Architect | Cambridge, MA | $170,000 | FY2026 Q1 |
| I-200-25307-362223 | Certified | Nov 14, 2025 | Head of S&OP “ Neuroscience and Established Brands | Lexington, MA | $180,000 | FY2026 Q1 |
| I-200-25310-382198 | Certified | Nov 14, 2025 | Platform Architect | Cambridge, MA | $170,000 | FY2026 Q2 |
| I-200-25309-378104 | Certified | Nov 14, 2025 | Brand Insights and Analytics Lead, US Oncology | Cambridge, MA | $190,000 | FY2026 Q2 |
| I-200-25307-362223 | Certified | Nov 14, 2025 | Head of S&OP – Neuroscience and Established Brands | Lexington, MA | $180,000 | FY2026 Q2 |
| I-200-25309-378104 | Certified | Nov 14, 2025 | Brand Insights and Analytics Lead, US Oncology | Cambridge, MA | $190,000 | FY2026 Q1 |
| I-200-25273-345047 | Certified | Nov 7, 2025 | Assoc. Dir., Sci. & Competitive Analysis, Glbl Oncology | Cambridge, MA | $190,000 | FY2026 Q1 |
| I-200-25273-348795 | Certified | Nov 7, 2025 | DDT Engineer Strategy & Business Excellence | Lexington, MA | $169,366 | FY2026 Q1 |
| I-200-25273-348795 | Certified | Nov 7, 2025 | DDT Engineer Strategy & Business Excellence | Lexington, MA | $169,366 | FY2026 Q2 |
| I-200-25273-345047 | Certified | Nov 7, 2025 | Assoc. Dir., Sci. & Competitive Analysis, Glbl Oncology | Cambridge, MA | $190,000 | FY2026 Q2 |
| I-200-25106-872580 | Certified - Withdrawn | Nov 5, 2025 | Director, Global Oncology Forecasting | Cambridge, MA | $246,000 | FY2026 Q2 |
| I-200-25106-872580 | Certified - Withdrawn | Nov 5, 2025 | Director, Global Oncology Forecasting | Cambridge, MA | $246,000 | FY2026 Q1 |
Related sponsors
Employers with imported DOL LCA or PERM filings that also list Massachusetts worksites, weighted toward overlapping roles. Shared filing footprints are a research and discovery signal, not a hiring or sponsorship guarantee.
Primary source
LCA rows for Takeda Pharmaceuticals are imported from DOL OFLC LCA Disclosure Data, the official US Department of Labor disclosure dataset. See About data for source caveats and Source status for import freshness, or use the LCA and PERM database lookup to search records across employers, roles, SOC codes, cities, and states. To check whether a different company sponsors H-1B, run it through the H-1B sponsor checker or review the H-1B sponsor cost guide.
DOL OFLC performance pageDate retrieved: . Last verified: . Page updated: .
FAQ
The Takeda Pharmaceuticals LCA page summarizes imported Department of Labor labor-condition rows for this normalized employer, including roles, worksites, wages, case statuses, and source periods.
No. LCA certification is an official DOL labor-condition filing signal, but USCIS decides H-1B petitions separately. Use the page as employer research context, not as an approval record.
Searches like "Takeda Pharmaceuticals H-1B" or "Takeda Pharmaceuticals H-1B sponsor" are best read against this LCA filing activity, which reflects historical labor-condition signals at Takeda Pharmaceuticals. It is not a promise of future sponsorship or an indicator of any individual case outcome.
Yes. This Takeda Pharmaceuticals LCA lookup view shows imported official DOL labor-condition rows for the employer, including job titles, worksites, wage fields, case statuses, and source periods. For a broader LCA lookup across employers, roles, SOC codes, cities, and states, use the LCA and PERM database lookup.
For searches like "Takeda Pharmaceuticals H-1B salary", VisaSignal normalizes the imported LCA wage fields into a range — the 25th-to-75th-percentile band plus the lowest and highest observed values — instead of a single number. These are DOL-disclosed offered and prevailing wages spanning different roles, worksites, and wage units, so read the band as wage-distribution context, not a guaranteed offer or legal minimum.
No. A DOL-certified LCA is not the same as USCIS H-1B petition approval. It is an official labor-condition filing signal that should be interpreted with that limit.
No. PERM certification is one step in an employment-based green card process. It does not mean a green card, I-140 petition, or adjustment of status was approved.
No. Official filing history can show recent activity, roles, worksites, and wage signals, but it does not guarantee future sponsorship or predict legal outcomes.
LCA and PERM rows are filing signals, not USCIS approvals, green-card approvals, legal advice, or outcome predictions.